Chromos updates on progress with development of CHR-1103 for treatment of MS:
" Chromos Molecular Systems
Inc. (TSX: CHR) has taken several significant steps in the development of its
lead product candidate, CHR-1103. A humanized monoclonal antibody, CHR-1103 is
being developed for the acute treatment of relapsing forms of multiple
sclerosis (MS). Its unique mechanism of action has the potential to reduce the
severity of a relapse in patients with MS and also stem the residual
neurological damage that often accompanies relapse and leads to progression of
the disease.
Chromos recently completed its first meeting with officials from the U.S.
Food and Drug Administration (FDA). The two parties discussed Chromos' clinical
approach, proposed preclinical safety evaluation program and manufacture of
CHR-1103. Chromos is now moving forward with preclinical safety evaluation
studies in preparation for an Investigational New Drug (IND) application in Q3
2007.
Using its proprietary ACE System, Chromos engineered a stable clonal cell
line expressing its product, CHR-1103 and transferred it to AppTec for process
development, scale up and manufacture. The ACE System demonstrated the ability
to perform well in large-scale manufacturing, validating the use of the
platform for clinical and commercial scale manufacturing of biopharmaceuticals.
The Company is now preparing to begin its preclinical safety evaluation studies
with Charles River Laboratories.
Chromos has engaged two leading MS clinicians to act as clinical
consultants for its CHR-1103 program. Lily Jung, M.D. is the Medical Director
of the Seattle Neuroscience Institute at Swedish Medical Centre in Seattle, WA,
and a clinical associate professor in Neurology at the University of Washington
Medical School. Mariko Kita, M.D. is a clinical investigator and Director of
the Virginia Mason Multiple Sclerosis Center in Seattle, WA. Drs. Jung and Kita
will advise and assist with the clinical development of CH"......